Difference between revisions of "Team:AFCM-Egypt"
Aymanshafei (Talk | contribs) |
Aymanshafei (Talk | contribs) |
||
| Line 156: | Line 156: | ||
<section class="header" id="header"> | <section class="header" id="header"> | ||
<nav class="navbar navbar-default navbar-fixed-top"> | <nav class="navbar navbar-default navbar-fixed-top"> | ||
| − | <div class="container" style="width: | + | <div class="container" style="width:99%"> |
<div class="navbar-header"> | <div class="navbar-header"> | ||
<button type="button" id="navbar-toggle" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar" aria-expanded="false" aria-controls="navbar"> | <button type="button" id="navbar-toggle" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar" aria-expanded="false" aria-controls="navbar"> | ||
| Line 168: | Line 168: | ||
<div class="collapse navbar-collapse" id="navbar"> | <div class="collapse navbar-collapse" id="navbar"> | ||
| − | <a class="navbar-brand" href="https://2017.igem.org/Team:AFCM-Egypt"><span><img src="https://static.igem.org/mediawiki/2017/a/aa/AFCM-Egypt-LOGO.png" style="width: | + | <a class="navbar-brand" href="https://2017.igem.org/Team:AFCM-Egypt"><span><img src="https://static.igem.org/mediawiki/2017/a/aa/AFCM-Egypt-LOGO.png" style="width:130px; height:130px;"></span></a> |
<ul id="menu"> | <ul id="menu"> | ||
<li class="active"><a href="https://2017.igem.org/Team:AFCM-Egypt">HOME</a> </li> | <li class="active"><a href="https://2017.igem.org/Team:AFCM-Egypt">HOME</a> </li> | ||
Revision as of 10:01, 28 October 2017
Abstract
Competing endogenous RNA network : Potential entrants to gene editing in Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC) is the leading cause of cancer deaths worldwide & ranked first among cancers in males and next to breast cancer among females in Egypt based upon results of National Cancer Registry Program of Egypt. "Grabbing the problem from the roots" is the best way to decently describe the use of CRISPR, a special gene editing technique that we will be using to modulate a certain circRNA and adjust its gene expression, which is down-regulated in hepatocellular carcinoma. This in consequence modifies miRNA expression thus amending the mRNA gene expression; which is the visible problem in our trials. This will lead us to adopt a novel strategy for miRNA suppression by using circRNAs. This is accomplished by utilizing a synthetic circuit to give rise to a springboard in our battle against cancer.
